BIAXIN XL
LOE ApproachingNDAORALTABLET
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIAXIN XL is an oral tablet formulation of clarithromycin, a macrolide antibiotic approved in 1993 by AbbVie. The drug treats bacterial infections across respiratory, skin, and gastrointestinal indications. It works by inhibiting bacterial protein synthesis via ribosomal binding.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); team size and commercial investment likely declining or stabilizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BIAXIN XL offers minimal career growth and limited job openings as the product approaches LOE. This role is best suited for professionals managing mature, stable portfolios or supporting transition planning rather than driving innovation.
Brand ManagerField Sales Representative
Worked on BIAXIN XL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.